Patents by Inventor Yves Chapleur

Yves Chapleur has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9522909
    Abstract: The present invention relates to thiazolidinedione derivatives, to the processes for preparing same and to the therapeutic use thereof for preventing or treating cancer, and more specifically breast cancer. These compounds are of formula (I) and exhibit, at a concentration of 100 ?M, a hepatocyte viability preferably greater than 60%, preferably greater than 80% and more preferentially greater than 85%.
    Type: Grant
    Filed: January 25, 2013
    Date of Patent: December 20, 2016
    Assignees: UNIVERSITE DE LORRAINE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE—CNRS
    Inventors: Michel Boisbrun, Yves Chapleur, Andrea Bordessa, Stephane Flament, Isabelle Grillier-Vuissoz, Sandra Kuntz
  • Publication number: 20160031923
    Abstract: The present invention relates to glycoside-derived compounds, to the processes for preparing same and to the use thereof as prosthetic groups for radiolabelling biomolecules. These compounds are co-azido-alkyl 6-deoxy-6-[18F]-fluoroglycosides of formula (I), in which: k is equal to 2 or 3; n is an integer between 1 and 5; R is independently H or a C1-C5 alkyl group, m being an integer between 0 and 2 if k=2 and m between 0 and 3 if k=3; and X is chosen from the group comprising O, S, CH2 and NR?, in which R? is independently a C1-C5 alkyl group or an aryl group, including all the stereoisomers thereof.
    Type: Application
    Filed: July 2, 2013
    Publication date: February 4, 2016
    Applicants: UNIVERSITE DE LORRAINE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - CNRS
    Inventors: YVES CHAPLEUR, Sandrine LAMANDE, Charlotte COLLET, Françoise CHRETIEN
  • Publication number: 20140364465
    Abstract: The present invention relates to thiazolidinedione derivatives, to the processes for preparing same and to the therapeutic use thereof for preventing or treating cancer, and more specifically breast cancer. These compounds are of formula (I) and exhibit, at a concentration of 100 ?M, a hepatocyte viability preferably greater than 60%, preferably greater than 80% and more preferentially greater than 85%.
    Type: Application
    Filed: January 25, 2013
    Publication date: December 11, 2014
    Applicants: UNIVERSITE DE LORRAINE, CENTRE NATIONAL DE LA RECHERCH SCIENTIFIQUE - CNRS
    Inventors: Michel Boisbrun, Yves Chapleur, Andrea Bordessa, Stephane Flament, Isabelle Grillier-Vuissoz, Sandra Kuntz